Growth Hormone

Well Researched

Ipamorelin

IPA

Selective growth-hormone secretagogue.

Also known as: NNC 26-0161

Research dose range100–300 mcg per dose (research models)

Route studiedSubcutaneous

Study duration1–3× daily, multi-week studies

Storage2–8 °C reconstituted

Overview

Ipamorelin is a pentapeptide and highly selective growth-hormone secretagogue widely referenced for its clean GH-release profile with minimal effect on cortisol or prolactin.

Key research findings

The most selective GHRP studied to date — it stimulates GH release with minimal impact on cortisol, prolactin, or appetite, unlike earlier secretagogues such as GHRP-6. Commonly paired with a GHRH analog (e.g. CJC-1295) for amplified, pulsatile GH release in research.

Mechanism of action

Selectively activates the ghrelin/GH-secretagogue receptor to stimulate growth-hormone release without strong appetite or stress-hormone effects.

Molecular information

Weight711.85 Da

Length5 amino acids

TypeSelective GH secretagogue (GHRP)

Amino-acid sequenceAib-His-D-2-Nal-D-Phe-Lys-NH2

A pentapeptide acting at the ghrelin/GH-secretagogue receptor.

Pharmacokinetics

Peak: ~0.25 hoursHalf-life: ~2 hoursCleared: ~8 hours

Peak · 1hHalf-life · 7h

Illustrative relative-concentration model derived from published pharmacokinetic research. Curve is normalized and provided for educational comparison only — not a dosing schedule.

Research applications

Selective GH-release research
Body-composition studies
Secretagogue-combination investigations

Research protocols

Protocols summarized from published research models. Provided for scientific reference only — not dosing guidance for human use.

Research goalReference amountFrequencyRoute

Standard referenceAmount: 200–300 mcgFrequency: 1–3× dailyRoute: Subcutaneous

GHRH-combination referenceAmount: 100–200 mcg + CJC-1295Frequency: Per doseRoute: Subcutaneous

Observed effects timeline

Aggregated observations reported across research literature. Timing and magnitude vary by model and are not a guarantee of outcome.

Acute (per dose)
Sharp, pulsatile GH release reported within ~30 minutes of administration.
Week 2–4
Cumulative IGF-1 elevation reported with consistent multi-week dosing.
Ongoing
Pulsatile pattern preserved; effects taper after discontinuation.

Research compatibility

Describes how compounds are studied alongside one another in the literature. Not a recommendation to co-administer.

CJC-1295 (no DAC)

Frequently co-studied for pulsatile release.

Synergistic

GHRP-6

Redundant GH-secretagogue activity.

Avoid combination

BPC-157

Distinct pathways; co-studied in recovery contexts.

Synergistic

TB-500

Complementary for muscle recovery, tissue repair, and overall regeneration

Compatible

Sermorelin

Excellent combination - Sermorelin (GHRH) and Ipamorelin (GHRP) work through different receptor pathways, producing synergistic 3-5 fold increases in GH release

Synergistic

Tesamorelin

Synergistic GH stimulation possible. Monitor IGF-1 levels closely and consider dose adjustments to prevent excessive growth hormone elevation.

Monitor

How to reconstitute

Important

Reconstitute with bacteriostatic water, swirl gently, and refrigerate. Do not shake — agitation degrades the peptide.

1Allow the vial to reach room temperature (15–20 minutes).
2Swab the stopper with alcohol and let it air dry.
3Add bacteriostatic water slowly down the vial wall.
4Swirl gently until dissolved into a clear solution.
5Refrigerate at 2–8 °C and protect from light.

Open reconstitution calculator

Quality indicators

Uniform white powder

Lyophilized cake should be white to off-white without discoloration.

Clear solution

Reconstitutes to a clear, colorless, particle-free solution.

Cold-chain integrity

Reconstituted solution requires 2–8 °C storage.

Slight clumping

Small clumps that dissolve completely with gentle swirling are acceptable — shipping can cause minor compaction.

Collapsed or melted appearance

Powder that looks collapsed, melted, or stuck to the vial walls may have been exposed to heat in transit.

Cloudy after reconstitution

Persistent cloudiness, particles, or precipitate after gentle mixing can indicate a degraded or contaminated peptide.

Reported observations & safety

Safety signals reported in the research literature. Compiled for scientific awareness — not medical advice.

Among the best-tolerated secretagogues in research, with minimal cortisol/prolactin impact.
Mild injection-site reactions and transient head-rush are occasionally reported.

References & further reading

Ipamorelin: a selective GH secretagogue (European Journal of Endocrinology, 1998)

Preclinicalselective GH releaselow cortisol/prolactin

Foundational study characterizing ipamorelin's selective growth-hormone-releasing profile relative to other GHRPs.

View study

Topics

secretagogueselectivegrowth hormone

This entry is provided for educational and informational purposes only. It is not medical advice, a dosing protocol, or a claim of therapeutic benefit. Research compounds are supplied strictly for laboratory and research use — not for human or veterinary consumption.

Research level

Well Researched

Substantial peer-reviewed research across multiple models.

Quick reference

Dose range100–300 mcg per dose (research models)

RouteSubcutaneous

Duration1–3× daily, multi-week studies

Storage2–8 °C reconstituted

Half-life~2 hours

Available at Reviva

Ipamorelin is stocked as a research-grade compound, ≥99% by HPLC, third-party verified.

View in catalogue